vs

Side-by-side financial comparison of FINANCIAL INSTITUTIONS INC (FISI) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $62.7M, roughly 1.1× FINANCIAL INSTITUTIONS INC). FINANCIAL INSTITUTIONS INC runs the higher net margin — 33.5% vs -49.0%, a 82.5% gap on every dollar of revenue.

The Mizuho Financial Group, Inc. , known from 2000 to 2003 as Mizuho Holdings and abbreviated as MHFG or simply Mizuho, is a Japanese banking holding company headquartered in the Ōtemachi district of Chiyoda, Tokyo, Japan. The group was formed in 2000–2002 by merger of Dai-Ichi Kangyo Bank, Fuji Bank, and Industrial Bank of Japan. The name mizuho (瑞穂) literally means "abundant rice" in Japanese and "harvest" in the figurative sense.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

FISI vs VRDN — Head-to-Head

Bigger by revenue
VRDN
VRDN
1.1× larger
VRDN
$70.6M
$62.7M
FISI
Higher net margin
FISI
FISI
82.5% more per $
FISI
33.5%
-49.0%
VRDN

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
FISI
FISI
VRDN
VRDN
Revenue
$62.7M
$70.6M
Net Profit
$21.0M
$-34.6M
Gross Margin
Operating Margin
-56.7%
Net Margin
33.5%
-49.0%
Revenue YoY
81958.1%
Net Profit YoY
24.3%
54.9%
EPS (diluted)
$1.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FISI
FISI
VRDN
VRDN
Q1 26
$62.7M
Q4 25
$64.1M
Q3 25
$63.8M
$70.6M
Q2 25
$59.7M
Q1 25
$57.2M
Q4 24
$41.6M
Q3 24
$50.1M
Q2 24
$65.2M
Net Profit
FISI
FISI
VRDN
VRDN
Q1 26
$21.0M
Q4 25
$20.0M
Q3 25
$20.5M
$-34.6M
Q2 25
$17.5M
Q1 25
$16.9M
Q4 24
$-82.8M
Q3 24
$13.5M
Q2 24
$25.6M
Operating Margin
FISI
FISI
VRDN
VRDN
Q1 26
Q4 25
37.4%
Q3 25
39.5%
-56.7%
Q2 25
36.0%
Q1 25
36.0%
Q4 24
-276.9%
Q3 24
29.0%
Q2 24
46.2%
Net Margin
FISI
FISI
VRDN
VRDN
Q1 26
33.5%
Q4 25
38.3%
Q3 25
32.1%
-49.0%
Q2 25
29.3%
Q1 25
29.5%
Q4 24
-198.9%
Q3 24
26.9%
Q2 24
39.3%
EPS (diluted)
FISI
FISI
VRDN
VRDN
Q1 26
$1.04
Q4 25
$0.96
Q3 25
$0.99
Q2 25
$0.85
Q1 25
$0.81
Q4 24
$-5.32
Q3 24
$0.84
Q2 24
$1.62

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FISI
FISI
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$85.5M
$490.9M
Total DebtLower is stronger
$114.0M
Stockholders' EquityBook value
$503.0M
Total Assets
$6.3B
$577.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FISI
FISI
VRDN
VRDN
Q1 26
$85.5M
Q4 25
$108.8M
Q3 25
$185.9M
$490.9M
Q2 25
$93.0M
Q1 25
$167.4M
Q4 24
$87.3M
Q3 24
Q2 24
Total Debt
FISI
FISI
VRDN
VRDN
Q1 26
$114.0M
Q4 25
$193.7M
Q3 25
$115.0M
Q2 25
$115.0M
Q1 25
$124.9M
Q4 24
$124.8M
Q3 24
$124.8M
Q2 24
$124.7M
Stockholders' Equity
FISI
FISI
VRDN
VRDN
Q1 26
Q4 25
$628.9M
Q3 25
$621.7M
$503.0M
Q2 25
$601.7M
Q1 25
$589.9M
Q4 24
$569.0M
Q3 24
$500.3M
Q2 24
$467.7M
Total Assets
FISI
FISI
VRDN
VRDN
Q1 26
$6.3B
Q4 25
$6.3B
Q3 25
$6.3B
$577.1M
Q2 25
$6.1B
Q1 25
$6.3B
Q4 24
$6.1B
Q3 24
$6.2B
Q2 24
$6.1B
Debt / Equity
FISI
FISI
VRDN
VRDN
Q1 26
Q4 25
0.31×
Q3 25
0.18×
Q2 25
0.19×
Q1 25
0.21×
Q4 24
0.22×
Q3 24
0.25×
Q2 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FISI
FISI
VRDN
VRDN
Operating Cash FlowLast quarter
$-84.6M
Free Cash FlowOCF − Capex
$-84.7M
FCF MarginFCF / Revenue
-120.1%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FISI
FISI
VRDN
VRDN
Q1 26
Q4 25
$18.8M
Q3 25
$-6.9M
$-84.6M
Q2 25
$-5.7M
Q1 25
$10.0M
Q4 24
$77.1M
Q3 24
$2.1M
Q2 24
$35.7M
Free Cash Flow
FISI
FISI
VRDN
VRDN
Q1 26
Q4 25
$13.3M
Q3 25
$-7.9M
$-84.7M
Q2 25
$-7.3M
Q1 25
$9.2M
Q4 24
$72.2M
Q3 24
$-299.0K
Q2 24
$34.7M
FCF Margin
FISI
FISI
VRDN
VRDN
Q1 26
Q4 25
20.7%
Q3 25
-12.4%
-120.1%
Q2 25
-12.3%
Q1 25
16.1%
Q4 24
173.3%
Q3 24
-0.6%
Q2 24
53.3%
Capex Intensity
FISI
FISI
VRDN
VRDN
Q1 26
Q4 25
8.7%
Q3 25
1.6%
0.2%
Q2 25
2.7%
Q1 25
1.4%
Q4 24
11.9%
Q3 24
4.9%
Q2 24
1.5%
Cash Conversion
FISI
FISI
VRDN
VRDN
Q1 26
Q4 25
0.94×
Q3 25
-0.34×
Q2 25
-0.33×
Q1 25
0.59×
Q4 24
Q3 24
0.16×
Q2 24
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FISI
FISI

Net Interest Income$52.0M83%
Noninterest Income$10.7M17%

VRDN
VRDN

Segment breakdown not available.

Related Comparisons